Home / World Marketplace / Archive by category Global Health & Biotech (Page 2)

Archive by category Global Health & Biotech

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-’749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1 Teva is committed to advancing this [...]

Ascom appoints David Hale as new CEO

Ad hoc announcement pursuant to Art. 53 LR Baar, Switzerland, December 9, 2025 David Hale, an executive leader with a proven track record and over two decades of technology and industrial expertise, has been appointed by the Board of Directors of Ascom Holding AG as the new CEO of the Ascom Group. David Hale will join [...]

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, [...]

Geneva College of Longevity Science and DrVibe.ai Launch the GCLS AI Academy for Longevity Sciences

First Multi-Agent AI System for Higher Longevity Education to Offer Free Courses and Pave the Way for a Master’s Degree in AI in Healthcare New Website: https://gcls.ai GENEVA, Dec. 08, 2025 (Korea Bizwire) – The Geneva College of Longevity Science (GCLS), in partnership with DrVibe.ai, today announced the launch of the GCLS AI Academy for Longevity Sciences—the world’s first [...]

$Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting$

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time [...]

CAPHRA Raises Alarm over Legitimacy of WHO Tobacco Treaty

MANILA, Philippines, Dec. 08, 2025 (Korea Bizwire) – A damning analysis from the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), entitled “The FCTC Secretariat’s Deepening Legitimacy Problem”, exposes how the World Health Organization’s Framework Convention on Tobacco Control has been captured by American philanthropist-funded NGOs, fundamentally undermining the treaty’s credibility and harming global public health [...]

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

SPRING, Texas, Dec. 06, 2025 (Korea Bizwire) – Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today collaborative presentations at the 67th American Society of Hematology Annual Meeting and Exposition, in Orlando, Florida; with scientists from the Duke University School of Medicine in Durham, North Carolina; reporting data from preclinical studies [...]

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%. Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment [...]

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

SHANGHAI, Dec. 05, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (“NDA”) for the company’s product, roconkibart injection (a recombinant humanized anti-IL-17A monoclonal antibody injection, product code: [...]

Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response

WASHINGTON, Dec. 04, 2025 (Korea Bizwire) – The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to support the country’s response to its first-ever outbreak of Marburg virus disease. Marburg is a highly contagious hemorrhagic fever disease and can have a high case fatality rate of [...]